Company Overview: Abeona

Industry News

13 Nov

Abeona Management to Present at Multiple Conferences in November

NEW YORK and CLEVELAND, Nov. 13, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the Company’s senior management team will participate in the following conferences: Jefferies 2017 London Healthcare Conference...

Read more

9 Nov

Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA

Company Opens European Subsidiary in Spain to Support Global Clinical Development Nine subjects at global clinical sites enrolled to date with more than 2,000 days cumulative follow up assessed NEW YORK and CLEVELAND, Nov. 09, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing...

Read more

19 Oct

Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK and CLEVELAND, Oct. 19, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc.  (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, today announced the closing of its underwritten public offering with a gross offering size of approximately $92 million, which...

Read more

17 Oct

Abeona Therapeutics Announces Pricing of Public Offering of Common Stock

NEW YORK and CLEVELAND, Oct. 16, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, today announced the pricing of an underwritten public offering of five million shares of common stock at a public offering...

Read more

16 Oct

Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies

Nine global foundations collaborate to grant $13.85 million for the continued advancement of lead Sanfilippo gene therapy programs Company receives infusion of an additional $5 million from exercise of outstanding warrants, totaling $18.85 million in proceeds NEW YORK and CLEVELAND, Oct. 16, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc.  (ABEO), a...

Read more

28 Sep

Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102

–Strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation –Phillip B. Maples, Ph.D., to lead Abeona manufacturing, as VP of Therapeutics Development and Quality Management CLEVELAND, Sept. 28, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing...

Read more

17 Aug

Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017

NEW YORK and CLEVELAND, Aug. 17, 2017 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced it will host its inaugural Research and Development (R&D) Day event for the institutional investment community in New York...

Read more

Page 1 of 512345

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address